During the past decade, Vermont Cancer Center conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 12 clinical trials were completed, i.e. on average, 600% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 4 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vermont Cancer Center" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 48 trials, followed by "Children's Oncology Group" with 32 trials sponsored, "Radiation Therapy Oncology Group" with 32 trials sponsored, "National Institute on Drug Abuse (NIDA)" with 15 trials sponsored and "University of Vermont" with 15 trials sponsored. Other sponsors include 40 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vermont Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 141 trials as a collaborator, "Cancer and Leukemia Group B" with 18 trials as a collaborator, "University of Vermont" with 15 trials as a collaborator, "SWOG Cancer Research Network" with 10 trials as a collaborator and "National Institute on Drug Abuse (NIDA)" with 7 trials as a collaborator. Other collaborators include 32 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Vermont Cancer Center" are "Leukemia" (26 trials), "Opioid-Related Disorders" (22 trials), "Lymphoma" (19 trials), "Breast Cancer" (17 trials) and "Lung Cancer" (15 trials). Many other conditions were trialed in "Vermont Cancer Center" in a lesser frequency.

Most popular intervention types in "Vermont Cancer Center" are "Drug" (148 trials), "Radiation" (52 trials), "Biological" (45 trials), "Procedure" (40 trials) and "Behavioral" (6 trials). Other intervention types were less common.

The name of intervention was led by "radiation therapy" (48 trials), "cyclophosphamide" (26 trials), "etoposide" (23 trials), "filgrastim" (22 trials) and "Buprenorphine" (21 trials). Other intervention names were less common.

The vast majority of trials in "Vermont Cancer Center" are 158 trials for "All" genders, 15 trials for "Female" genders and 13 trials for "Male" genders.

Currently, there are NaN active trials in "Vermont Cancer Center". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 163 completed trials in Vermont Cancer Center, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Vermont Cancer Center, 23 "Phase 1" clinical trials were conducted, 101 "Phase 2" clinical trials and 58 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".